Choledochal Cyst

A choledochal cyst (choledochal malformation) is a congenital cystic or fusiform dilatation of the extrahepatic and/or intrahepatic bile ducts, most often due to an anomalous pancreaticobiliary junction that allows reflux of pancreatic enzymes into the biliary tree. It is classified by the Todani system into five types based on the site and morphology of ductal dilatation, with type I (extrahepatic fusiform dilatation) and type IVA (combined intra- and extrahepatic disease) being most common. Imaging — ultrasound in children, CT and MRI/MRCP in adults — is central to diagnosis, Todani typing, and detection of complications including stones, cholangitis, and malignant transformation.

Quick Reference

• Todani classification (5 types): Type I — cystic/fusiform dilatation of the extrahepatic common bile duct (most common, ~50–80%); Type II — true diverticulum off the extrahepatic duct; Type III (choledochocele) — dilatation confined to the intraduodenal/intrapancreatic common bile duct; Type IVA — multiple cysts involving both intrahepatic and extrahepatic ducts; Type IVB — multiple extrahepatic cysts only; Type V (Caroli disease) — multifocal intrahepatic ductal dilatation only.
• First-line modality: abdominal ultrasound in infants/children; CT often obtained first in adults, but MRCP is the diagnostic reference standard for anatomic delineation and surgical planning.
• MRCP accuracy for Todani typing: sensitivity/specificity of 81%/90% (type I), 73%/100% (type III), 83%/90% (type IVA), and 100%/100% (types IVB and V).
• Pathogenesis: anomalous pancreaticobiliary junction (long common channel) permitting pancreatic enzyme reflux into bile, causing chronic ductal wall injury and dilatation.
• Malignancy risk: overall lifetime risk of biliary malignancy (usually cholangiocarcinoma) is roughly 10–11%, rising with age — about 1% in the first decade, 15% after age 20, 26% after age 40, and up to 45.5% after age 70. Types I and IV carry the highest risk.
• Management implication: complete cyst excision (not internal drainage/cystenterostomy) is standard of care — cystic drainage alone carries roughly 4-fold higher odds of subsequent biliary malignancy.
• Report essentials: Todani type, presence/absence of intrahepatic ductal involvement, ductal stricture (particularly at the hepatic hilum in type IVA), stones/sludge, wall thickening or enhancement, common channel length, and any mass or nodular filling defect suspicious for malignancy.

Background

Choledochal cysts are rare congenital anomalies of the biliary tree, more common in East Asian populations and in females (female-to-male ratio approximately 3–4:1). Roughly 80% present in childhood, but adult presentation is not uncommon and often carries a higher complication and malignancy burden. The leading pathogenetic theory is an anomalous pancreaticobiliary junction (APBJ), in which the common bile duct and pancreatic duct join outside the duodenal wall, forming an abnormally long common channel. This anatomic variant allows pancreatic secretions to reflux into the biliary system, causing chronic inflammation, elevated intraluminal pressure, and progressive ductal ectasia.

Imaging Anatomy

Choledochal cysts are described relative to the normal biliary tree: intrahepatic ducts, the common hepatic duct, the common bile duct (further divided into supraduodenal, retroduodenal, and intrapancreatic segments), and the pancreaticobiliary junction where the common bile duct and pancreatic duct converge before entering the duodenum at the ampulla of Vater. Precise localization of dilatation relative to these landmarks is what separates the Todani subtypes:

• Type I — dilatation of the common hepatic and/or common bile duct, sparing the intrahepatic ducts; subclassified as cystic (Ia), focal segmental (Ic, associated with a primary stricture), or diffuse fusiform (If).
• Type II — a true saccular diverticulum arising from the wall of the extrahepatic duct, connected by a narrow stalk.
• Type III (choledochocele) — dilatation localized to the intraduodenal or intrapancreatic portion of the distal common bile duct, often bulging into the duodenal lumen near the ampulla.
• Type IVA — multiple dilated segments involving both the extrahepatic duct and one or more intrahepatic ducts.
• Type IVB — multiple dilated segments confined to the extrahepatic duct only.
• Type V (Caroli disease/syndrome) — multifocal saccular dilatation of the intrahepatic bile ducts without extrahepatic involvement; when accompanied by congenital hepatic fibrosis, it is termed Caroli syndrome.

Imaging Findings by Modality

Ultrasound

Ultrasound is the preferred initial study in infants and children because it is radiation-free and highly sensitive for biliary dilatation. It shows an anechoic, often septated cystic or tubular structure in the porta hepatis that communicates with the biliary tree — this communication is the key discriminator from other right-upper-quadrant cystic lesions (e.g., duplication cyst, hepatic cyst, pancreatic pseudocyst). Look for continuity with a dilated common bile duct, associated intrahepatic ductal dilatation (suggesting type IVA), gallstones or sludge within the cyst, and gallbladder wall thickening from associated cholecystitis or cholangitis.

CT

In adults, CT is frequently the first cross-sectional study obtained for nonspecific abdominal pain, and it readily depicts a large, well-marginated cystic or fusiform mass contiguous with the biliary tree, with variable intrahepatic ductal dilatation. Contrast-enhanced CT is useful for delineating the extent of disease, showing wall thickening or enhancing mural nodularity that should raise concern for superimposed cholangiocarcinoma, and identifying complications such as stones, pancreatitis, or perforation. CT is less reliable than MRCP for precise Todani subtyping and for characterizing the pancreaticobiliary junction.

MRI/MRCP

MRCP is the reference-standard noninvasive study for choledochal cysts and has essentially replaced diagnostic ERCP. Heavily T2-weighted MRCP sequences depict the full biliary tree without contrast or radiation, allowing direct visualization of cyst morphology, extent of intrahepatic involvement, the anomalous pancreaticobiliary junction and common channel length, ductal strictures (particularly important in type IVA, where hilar or intrahepatic strictures can be missed on CT), and intraductal filling defects from stones or tumor. Reported MRCP performance for Todani classification is high but imperfect (81–100% sensitivity depending on type), so correlation with cross-sectional MRI and clinical context remains important, especially for distinguishing type I from type IVA when subtle intrahepatic ductal dilatation is present. Post-contrast MRI adds value for detecting mural enhancement or a discrete mass suspicious for malignant transformation.

Differential Diagnosis and Imaging Pitfalls

• Simple hepatic cyst or duplication cyst — lacks communication with the biliary tree; choledochal cysts characteristically communicate.
• Caroli disease (isolated) vs choledochal cyst type IVA — Caroli disease has no extrahepatic component and shows the “central dot sign” (portal radicles surrounded by dilated ducts) on CT/MRI.
• Pancreatic pseudocyst — extrinsic to the biliary tree, associated with pancreatitis history and a different anatomic relationship to the duct.
• Choledocholithiasis with obstructive ductal dilatation — dilatation here is typically less saccular/focal and resolves with stone clearance, unlike the fixed congenital dilatation of a choledochal cyst.
• Missed intrahepatic component — failing to trace intrahepatic ducts on MRCP can lead to under-typing a type IVA cyst as type I, which changes surgical planning.
• Superimposed cholangiocarcinoma — can be subtle, presenting only as focal wall thickening, mural nodularity, or a stricture rather than a discrete mass; a high index of suspicion is warranted, especially in adults with long-standing cysts.

Clinical Impact and Reporting

Accurate Todani typing on imaging directly determines the surgical approach: types I and IV generally require complete cyst excision with hepaticojejunostomy, type II may be managed with simple diverticulectomy, type III (choledochocele) is often amenable to endoscopic management, and type V (Caroli disease) may require segmental hepatectomy or, in diffuse bilobar disease, transplantation. Because internal drainage procedures (cystenterostomy) leave abnormal biliary mucosa in continuity with the bowel and carry a markedly higher long-term malignancy risk, radiology reports should clearly state the Todani type, the extent of intrahepatic ductal involvement, and any features suspicious for malignancy so this can inform complete excision versus a more limited approach. Given the decades-long latency to malignant transformation, imaging surveillance remains relevant even after prior partial treatment.

Frequently Asked Questions

What is the most common type of choledochal cyst?

Type I, characterized by cystic or fusiform dilatation of the extrahepatic common hepatic and/or common bile duct without intrahepatic involvement, accounts for the majority of cases, estimated at roughly 50–80% depending on the series.

What imaging modality is best for diagnosing a choledochal cyst?

Ultrasound is the preferred first-line study in children due to its safety and sensitivity for ductal dilatation, while MRI with MRCP is the reference standard overall, providing the most accurate delineation of cyst extent, the anomalous pancreaticobiliary junction, and any associated strictures for surgical planning.

How is a choledochocele (type III) different from other choledochal cysts?

A choledochocele is dilatation confined to the intraduodenal or intrapancreatic segment of the distal common bile duct, often bulging into the duodenal lumen near the ampulla, and is frequently managed endoscopically rather than with the surgical excision used for types I, II, and IV.

Do choledochal cysts increase cancer risk?

Yes. The overall risk of biliary malignancy, most often cholangiocarcinoma, is approximately 10–11% and increases substantially with patient age and with prior cystic drainage procedures rather than complete excision.

Is Caroli disease the same as a choledochal cyst?

Caroli disease (Todani type V) is considered part of the choledochal cyst spectrum but is distinct in that dilatation is confined to the intrahepatic ducts with no extrahepatic component; when combined with congenital hepatic fibrosis, it is termed Caroli syndrome.

Can choledochal cysts be diagnosed prenatally?

Yes, prenatal ultrasound can detect a choledochal cyst as a right-upper-quadrant cystic structure in the fetus, and MRI has been used to further characterize suspected cases, though postnatal imaging is still needed to confirm biliary communication and Todani type.

References

1. Todani T, Watanabe Y, Narusue M, Tabuchi K, Okajima K. Congenital bile duct cysts: classification, operative procedures, and review of thirty-seven cases including cancer arising from choledochal cyst. Am J Surg. 1977;134(2):263-269. PMID: 889044.
2. Kim OH, Chung HJ, Choi BG. Imaging of the choledochal cyst. RadioGraphics. 1995;15(1):69-88. PMID: 7899614.
3. Soares KC, et al. Imaging of choledochal cysts. Abdom Imaging (Abdom Radiol). 2015. PMID: 25682292.
4. Ozel A, et al. A new variant of Todani type I choledochal cyst. Imaging evaluation. PMID: 22110303.
5. Kim MJ, et al. Can MRCP replace the diagnostic role of ERCP for patients with choledochal cysts? Gastrointest Endosc. 2005. PMID: 16111952.
6. Kim SH, et al. Imaging features of adult choledochal cysts: a pictorial review. PMID: 19182506.
7. Todani T, et al. Classification of congenital biliary cystic disease: special reference to type Ic and IVA cysts with primary ductal stricture. J Hepatobiliary Pancreat Surg. 2003. PMID: 14598133.
8. ten Hove A, de Meijer VE, Hulscher JBF, de Kleine RHJ. Meta-analysis of risk of developing malignancy in congenital choledochal malformation. Br J Surg. 2018;105(5):482-490. PMID: 29480528.
9. Choledochal cysts in adults: magnetic resonance imaging of cyst complications and review of management strategies. Abdom Radiol. 2025. PMID: 40459594.